{"id":115988,"date":"2026-11-03T11:50:28","date_gmt":"2026-11-03T09:50:28","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=115988"},"modified":"2026-11-03T12:29:42","modified_gmt":"2026-11-03T10:29:42","slug":"ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/","title":{"rendered":"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &#8220;bien&#8221;, est-ce encore suffisant ?"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>Gr\u00e2ce \u00e0 la recherche clinique, \u00e0 la collaboration avec des experts et \u00e0 des initiatives ax\u00e9es sur les patients, Ipsen s&#8217;emploie \u00e0 am\u00e9liorer les r\u00e9sultats et \u00e0 \u00e9lever les standards de soins pour les personnes vivant avec des maladies rares du foie.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>De nouvelles donn\u00e9es soutiennent une \u00e9volution majeure dans la prise en charge des patients : il ne s&#8217;agit plus simplement de maintenir les taux sanguins de phosphatase alcaline (PAL) \u2013 un biomarqueur de la maladie \u2013 dans une fourchette acceptable, mais de viser la normalisation des taux de PAL, nouvelle norme pour am\u00e9liorer la sant\u00e9 \u00e0 long terme dans la cholangite biliaire primitive (CBP).<sup>1<\/sup>&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Au-del\u00e0 des soins p\u00e9diatriques traditionnels, la prise de conscience croissante que des maladies g\u00e9n\u00e9tiques rares telles que la cholestase intrah\u00e9patique familiale progressive (PFIC) et le syndrome d&#8217;Alagille (ALGS) peuvent se manifester chez les adolescents et les adultes est en train de red\u00e9finir les approches en mati\u00e8re de diagnostic et de prise en charge.<sup>2,3<\/sup>&nbsp;<\/li>\n<\/ul>\n\n\n<p class=\"heading-para wp-block-paragraph\">Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l&#8217;avenir de l&#8217;h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.\u00a0<\/p>\n\n    <section class=\"title-text \">\n        <div class=\"container\">\n            <div class=\"title-text-inner\" style=\"background-color:#EDEBE4;\">\n\n                <!-- If heading is enabled then it's visible -->\n                <div class=\"text-head-dash visible\">\n                <h3 class=\"heading-three\" role=\"heading\" aria-level=\"2\">\n                        Une nouvelle ambition pour la prise en charge de la CBP                     <\/h3>\n                <\/div>\n               \n                <!-- If description is enabled then it's visible -->\n                <div class=\"text-parbase visible\">\n                    <p><span data-contrast=\"auto\">Nous assistons actuellement \u00e0 un changement profond dans notre approche du traitement de la CBP. Pendant des ann\u00e9es, les recommandations cliniques se sont concentr\u00e9es sur la r\u00e9duction des taux de PAL (une enzyme servant de marqueur de l&#8217;activit\u00e9 de la maladie dans la CBP) pour \u00e9valuer l&#8217;efficacit\u00e9 des traitements.<sup>4,5<\/sup> Aujourd&#8217;hui, cette ambition \u00e9volue.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Il existe un consensus croissant parmi les experts sur le fait que viser la normalisation des taux de PAL, plut\u00f4t que leur simple diminution, est non seulement r\u00e9alisable, mais devrait \u00eatre l&#8217;objectif de r\u00e9f\u00e9rence pour pr\u00e9server la sant\u00e9 du foie \u00e0 long terme.<\/span><sup><span data-contrast=\"auto\">1,6<\/span><\/sup><span data-contrast=\"auto\"> Cependant, la gestion de ces aspects biochimiques ne repr\u00e9sente que la moiti\u00e9 du chemin. Nous nous engageons \u00e0 soutenir une approche plus globale, o\u00f9 les m\u00e9decins ne traitent pas uniquement les taux de PAL, mais s&#8217;attaquent aussi aux sympt\u00f4mes pesants, comme la fatigue et le prurit, qui peuvent profond\u00e9ment alt\u00e9rer la qualit\u00e9 de vie des patients.<\/span><sup><span data-contrast=\"auto\">7,8<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/sup><\/p>\n                <\/div>\n\n                <!-- If button is enabled then it's visible -->\n                \n            <\/div>\n        <\/div>\n    <\/section>\n\n\n\n<!--Alert Card Layout Start Here-->\n<section class=\"alertcard-section\">\n      <div class=\"container\">\n        <!--Alert Box HTML Start Here-->\n        <div class=\"alert-box general-box\">\n                  <div class=\"info-contents\">\n                            <h4 role=\"heading\" aria-level=\"2\" class=\"info-head heading-four heading-four\">\n                    Faire \u00e9voluer les perceptions sur la PFIC et l&#8217;ALGS                 <\/h4>\n                                      <div class=\"alert-content visible\">\n                  <p><span data-contrast=\"auto\">L&#8217;un des obstacles les plus tenaces dans la prise en charge des maladies rares est l&#8217;id\u00e9e re\u00e7ue selon laquelle les maladies g\u00e9n\u00e9tiques, telles que la CIFP et l&#8217;ALGS, ne touchent que les enfants.<\/span><span data-ccp-props=\"{&quot;335559739&quot;:100}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u00c0 cause de cette perception, de nombreux adolescents et adultes pr\u00e9sentant une cholestase (anomalie de l&#8217;\u00e9coulement de la bile depuis le foie) inexpliqu\u00e9e se retrouvent souvent sans diagnostic pr\u00e9cis. Une meilleure sensibilisation, le recours aux tests g\u00e9n\u00e9tiques lorsque cela est pertinent et le d\u00e9veloppement de meilleurs outils de d\u00e9tection pourraient aider un plus grand nombre de personnes \u00e0 obtenir un diagnostic exact et \u00e0 b\u00e9n\u00e9ficier d&#8217;une prise en charge sp\u00e9cialis\u00e9e ad\u00e9quate.<\/span><sup><span data-contrast=\"auto\">3,4<\/span><span data-ccp-props=\"{&quot;335559739&quot;:100}\">\u00a0<\/span><\/sup><\/p>\n<p><span data-contrast=\"auto\">Notre approche va au-del\u00e0 de la recherche ; elle s&#8217;ancre dans le partenariat. Nous g\u00e9n\u00e9rons en permanence des donn\u00e9es en vie r\u00e9elle, soutenons la formation m\u00e9dicale ind\u00e9pendante et collaborons avec des associations de patients pour faire en sorte que le v\u00e9cu des personnes atteintes de maladies rares du foie \u00e9claire directement les d\u00e9cisions cliniques.<\/span><\/p>\n              <\/div>\n          <\/div>\n        <\/div>\n        <!--Alert Box HTML Start Here-->\n      <\/div>\n    <\/section>\n<!--Alert Card Layout End Here-->\n\n\n\n<h3 class=\"wp-block-heading heading-three\"><strong>Quelles avanc\u00e9es scientifiques retenir de l&#8217;AASLD The Liver Meeting 2026 ?<\/strong>\u00a0<\/h3>\n\n<p class=\"heading-para wp-block-paragraph\">D\u00e9couvrez les analyses quotidiennes de Hugo Gomes da Silva, Vice-pr\u00e9sident senior, Affaires M\u00e9dicales Mondiales (Maladies Rares) chez Ipsen, en direct de The Liver Meeting 2026. Il revient sur les moments forts du congr\u00e8s et partage ses r\u00e9flexions sur les donn\u00e9es qui fa\u00e7onnent l&#8217;avenir des soins h\u00e9patiques. <strong>Bient\u00f4t disponible<\/strong><\/p>\n\n<h3 class=\"wp-block-heading heading-three\"><strong>Que disent les experts sur l&#8217;avenir de la prise en charge des maladies rares du foie ?<\/strong>\u00a0<\/h3>\n\n<p class=\"heading-para wp-block-paragraph\">\u00c9coutez les grands noms de l&#8217;h\u00e9patologie discuter de l&#8217;\u00e9volution du paysage des maladies rares du foie \u2013 enregistr\u00e9 en direct de The Liver Meeting 2026.\u00a0<\/p>\n\n<p class=\"has-white-color has-text-color has-link-color wp-elements-1 heading-para wp-block-paragraph\">.<\/p>\n\n<p class=\"has-white-color has-text-color has-link-color wp-elements-2 heading-para wp-block-paragraph\">.<\/p>\n\n    <section class=\"title-text \">\n        <div class=\"container\">\n            <div class=\"title-text-inner\" style=\"background-color:#EDEBE4;\">\n\n                <!-- If heading is enabled then it's visible -->\n                <div class=\"text-head-dash visible\">\n                <h3 class=\"heading-three\" role=\"heading\" aria-level=\"2\">\n                        Comment Ipsen a contribu\u00e9 \u00e0 la recherche sur les maladies rares du foie au fil des ann\u00e9es ?                     <\/h3>\n                <\/div>\n               \n                <!-- If description is enabled then it's visible -->\n                <div class=\"text-parbase visible\">\n                    <p><span data-contrast=\"auto\">Notre pr\u00e9sence \u00e0 The Liver Meeting illustre notre soutien de longue date envers la communaut\u00e9 scientifique et notre engagement \u00e0 transformer la vie des patients atteints de maladies rares du foie.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">D\u00e9couvrez notre biblioth\u00e8que de sessions d&#8217;experts, de posters num\u00e9riques et d&#8217;analyses scientifiques issus des congr\u00e8s pr\u00e9c\u00e9dents.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n                <\/div>\n\n                <!-- If button is enabled then it's visible -->\n                                        <div class=\"btn-txt\">\n                            <a \n                                aria-label=\"\" \n                                class=\"btn-link section-btn cta-visible\"  \n                                role=\"link\"\n                                href=\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-liver-meeting-2025\/\" target=\"_blank\">\n                                D\u00e9couvrez nos pr\u00e9c\u00e9dentes activit\u00e9s \u00e0 l&#039;AASLD                            <\/a>\n                        <\/div>\n                \n            <\/div>\n        <\/div>\n    <\/section>\n\n\n<p class=\"heading-para wp-block-paragraph\"><strong>R\u00e9f\u00e9rences<\/strong>\u00a0<\/p>\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><em>Kowdley K, et al. Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial. Hepatol. 2026. [Ahead of publication] <a href=\"https:\/\/www.doi.org\/10.1097\/HEP.0000000000001906\" target=\"_blank\" rel=\"noopener\">https:\/\/www.doi.org\/10.1097\/HEP.0000000000001906<\/a>.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"2\" class=\"wp-block-list\">\n<li><em>Ayoub MD, et al. Management of adults with Alagille syndrome. Hepatol Commun. 2023;8(5 ):e0435.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"3\" class=\"wp-block-list\">\n<li><em>Berg T. Progressive Familial Intrahepatic Cholestasis in Adulthood: Genetics, Diagnosis, Treatment, and Further Research. EMJ Hepatology. 2024;12:2-7.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"4\" class=\"wp-block-list\">\n<li><em>Kowdley KV, et al. Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: A population-based study. Aliment Pharmacol Ther. 2025;61(6 ):1775-1784.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"5\" class=\"wp-block-list\">\n<li><em>Younossi ZM, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114(1 ):48-63.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"6\" class=\"wp-block-list\">\n<li><em>Perez CFM, et al. Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol. 2020;115(7):1066-1074.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"7\" class=\"wp-block-list\">\n<li><em>Hirschfield GM, Beuers U and Corpechot C, et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology. 2017;67:145-172.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"8\" class=\"wp-block-list\">\n<li><em>Younossi ZM, et al. Assessment of fatigue and its impact in chronic liver disease. J Hepatol. 2024;81(4 ):726-742.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"9\" class=\"wp-block-list\">\n<li><em>V\u00f6gelin M and Kremer AE. Advancing care in primary biliary cholangitis: Emerging insights and novel therapies. Expert Opin Pharmacother. 2025;26(1):15-28.&nbsp;<\/em><\/li>\n<\/ol>\n\n\n\n<ol start=\"10\" class=\"wp-block-list\">\n<li><em>Trivella J, John BV, Levy C. Primary biliary cholangitis: Epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6 ):e0179.&nbsp;&nbsp;<\/em><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les<\/p>\n","protected":false},"author":11,"featured_media":91037,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[1192],"tags":[],"class_list":["post-115988","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-rare-diseases-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &quot;bien&quot;, est-ce encore suffisant ? - Global<\/title>\n<meta name=\"description\" content=\"Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l&#039;avenir de l&#039;h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &quot;bien&quot;, est-ce encore suffisant ? - Global\" \/>\n<meta property=\"og:description\" content=\"Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l&#039;avenir de l&#039;h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-03T09:50:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T10:29:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"heloisedetouchet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"heloisedetouchet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/\"},\"author\":{\"name\":\"heloisedetouchet\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#\\\/schema\\\/person\\\/2c275168b31beee81688f3c041877318\"},\"headline\":\"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &#8220;bien&#8221;, est-ce encore suffisant ?\",\"datePublished\":\"2026-11-03T09:50:28+00:00\",\"dateModified\":\"2026-11-03T10:29:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/\"},\"wordCount\":609,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ipsen.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg\",\"articleSection\":[\"Maladies Rares\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/\",\"name\":\"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de \\\"bien\\\", est-ce encore suffisant ? - Global\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ipsen.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg\",\"datePublished\":\"2026-11-03T09:50:28+00:00\",\"dateModified\":\"2026-11-03T10:29:42+00:00\",\"description\":\"Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l'avenir de l'h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ipsen.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg\",\"width\":700,\"height\":420},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/actualites\\\/rare-diseases-fr\\\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &#8220;bien&#8221;, est-ce encore suffisant ?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ipsen.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\\\/\\\/www.ipsen.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/Ipsengroup\",\"https:\\\/\\\/x.com\\\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ipsen.com\\\/fr\\\/#\\\/schema\\\/person\\\/2c275168b31beee81688f3c041877318\",\"name\":\"heloisedetouchet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g\",\"caption\":\"heloisedetouchet\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de \"bien\", est-ce encore suffisant ? - Global","description":"Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l'avenir de l'h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de \"bien\", est-ce encore suffisant ? - Global","og_description":"Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l'avenir de l'h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.","og_url":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/","og_site_name":"Global","article_published_time":"2026-11-03T09:50:28+00:00","article_modified_time":"2026-11-03T10:29:42+00:00","og_image":[{"width":700,"height":420,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg","type":"image\/jpeg"}],"author":"heloisedetouchet","twitter_card":"summary_large_image","twitter_creator":"@ipsengroup","twitter_site":"@ipsengroup","twitter_misc":{"Written by":"heloisedetouchet","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/"},"author":{"name":"heloisedetouchet","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/2c275168b31beee81688f3c041877318"},"headline":"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &#8220;bien&#8221;, est-ce encore suffisant ?","datePublished":"2026-11-03T09:50:28+00:00","dateModified":"2026-11-03T10:29:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/"},"wordCount":609,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg","articleSection":["Maladies Rares"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/","url":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/","name":"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de \"bien\", est-ce encore suffisant ? - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg","datePublished":"2026-11-03T09:50:28+00:00","dateModified":"2026-11-03T10:29:42+00:00","description":"Les maladies rares du foie sont souvent complexes, \u00e9volutives et fr\u00e9quemment sous-diagnostiqu\u00e9es, ce qui engendre des d\u00e9fis majeurs pour les personnes qui en sont atteintes. Chez Ipsen, nous sommes d\u00e9termin\u00e9s \u00e0 changer la donne. En associant notre leadership scientifique \u00e0 une compr\u00e9hension approfondie des besoins des patients, nous \u0153uvrons pour fa\u00e7onner l'avenir de l'h\u00e9patologie et contribuer \u00e0 \u00e9lever les standards de soins \u00e0 travers le monde.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg","width":700,"height":420},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ipsen-au-congres-the-liver-meeting-2026-se-content-de-bien-est-ce-encore-suffisant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen au congr\u00e8s The Liver Meeting 2026 : se contenter de &#8220;bien&#8221;, est-ce encore suffisant ?"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/2c275168b31beee81688f3c041877318","name":"heloisedetouchet","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a294050dc7df14814ce352dcd30bd2b11c1bf6f269c4edf2111b59216f02bb15?s=96&d=mm&r=g","caption":"heloisedetouchet"}}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2025\/10\/Franchise_Key_visuals_\u2013_Rare_Liver_Disease_Digital-none.jpg","permalink_manager":null,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/115988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/comments?post=115988"}],"version-history":[{"count":3,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/115988\/revisions"}],"predecessor-version":[{"id":115992,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/115988\/revisions\/115992"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/91037"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=115988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=115988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=115988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}